Biomedical subjects
J Rivier
Publications and source records attributed to J Rivier.
TOTAL SYNTHESIS OF THE HYPOTHALAMIC THYROTROPIN RELEASING FACTOR.
Explore the source record for details and available documents.
Somatostatin analogs. Relative importance of the disulfide bridge and of the Ala-Gly side chain for biological activity.
Four analogs of ovine somatostatin (SRIF, PSOMATOTROPIN RELEASE INhibiting factor), the sequence of which is H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-trp-Lys-Thr-Phe-Thr-Ser-Cys-OH, have been synthesized by the solid-phase methodology. The compounds were assayed and were found to possess the following somatotropin release inhibiting potencies relative to pure synthetic somatostatin in vitro and in vivo, respectively: [Ala3,14]somatostatin, 0.6 and 2.0%; [SMe-Cys3,14]somatostatin, 4 and 0.6%; [NAc-Cys3]somatostatin, 39 and 105%; [des-Ala1-Gly2]somatostatin, 65 and 71%. The dihydrosomatostatin analogs [NAc-Cys3-H2]somatostatin and [des-Ala1Gly2-H2]somatostatin after two purifications by gel filtration were assessed to be at least 80% homogeneous and had respectively 99 and 89% of somatostatin potencied in vivo. Structure-activity relationships are discussed.
Acylated des-(Ala1-Gly2)-somatostatin analogs: prolonged inhibition of growth hormone secretion.
Explore the source record for details and available documents.
Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications.
Explore the source record for details and available documents.
Biological potency of synthetic somatostatin in the oxidized and reduced form on the inhibition of secretion of growth hormone.
Explore the source record for details and available documents.
Conformational studies on the hypothalamic thyrotropin releasing factor and related compounds by 1-H nuclear magnetic resonance spectroscopy.
Explore the source record for details and available documents.
Synthetic luteinizing hormone releasing factor. Short chain analogs.
Explore the source record for details and available documents.
Inhibition of growth hormone secretion in the rat by synthetic somatostatin.
Explore the source record for details and available documents.
Inhibition of the sleep-related peak in physiologic human growth hormone release by somatostatin.
Explore the source record for details and available documents.
Direct sequence determination of ovine luteinizing hormone releasing factor by mass spectrometry.
Explore the source record for details and available documents.
[Solid-phase total synthesis of a tetradecapeptide having the chemical and biological properties of somatostatine].
Explore the source record for details and available documents.
Pituitary binding sites for ( 3 H)-labelled luteinizing hormone releasing factor (LRF).
Explore the source record for details and available documents.
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone.
A peptide has been isolated from ovine hypothalamus which, at 1 x 10(-9)M, inhibits secretion in vitro of immunoreactive rat or human growth hormones and is similarly active in vivo in rats. Its structure is H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH The synthetic replicate is biologically active.
The use of mass spectrometry in deducing the sequence of somatostatin--a hypothalamic polypeptide that inhibits the secretion of growth hormone.
Explore the source record for details and available documents.
Chemistry of hypothalamic releasing factors.
Explore the source record for details and available documents.
Synthetic luteinizing hormone-releasing factor analogs. Series of short-chain amide LRF homologs converging to the amino terminus.
Explore the source record for details and available documents.
Angiotensin II. Synthesis and biological activity of 6-(1-methylhistidine) and 6-(3-methylhistidine) analogs.
Explore the source record for details and available documents.